Cargando…

Preclinical models of epithelial ovarian cancer: practical considerations and challenges for a meaningful application

Despite many improvements in ovarian cancer diagnosis and treatment, until now, conventional chemotherapy and new biological drugs have not been shown to cure the disease, and the overall prognosis remains poor. Over 90% of ovarian malignancies are categorized as epithelial ovarian cancers (EOC), a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ciucci, Alessandra, Buttarelli, Marianna, Fagotti, Anna, Scambia, Giovanni, Gallo, Daniela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9200670/ https://www.ncbi.nlm.nih.gov/pubmed/35705879 http://dx.doi.org/10.1007/s00018-022-04395-y

Ejemplares similares

Exploring the Control of PARP1 Levels in High-Grade Serous Ovarian Cancer
por: Raspaglio, Giuseppina, et al.
Publicado: (2023)

Clinical Value of lncRNA MEG3 in High-Grade Serous Ovarian Cancer
por: Buttarelli, Marianna, et al.
Publicado: (2020)

Identification of a novel gene signature predicting response to first-line chemotherapy in BRCA wild-type high-grade serous ovarian cancer patients
por: Buttarelli, Marianna, et al.
Publicado: (2022)

Multiple direct and indirect mechanisms drive estrogen-induced tumor growth in high grade serous ovarian cancers
por: Ciucci, Alessandra, et al.
Publicado: (2016)

Ovarian low and high grade serous carcinomas: hidden divergent features in the tumor microenvironment
por: Ciucci, Alessandra, et al.
Publicado: (2016)

KLF7: a new candidate biomarker and therapeutic target for high-grade serous ovarian cancer
por: De Donato, Marta, et al.
Publicado: (2020)

Laparoscopic selection for surgery in epithelial ovarian cancer. A short review
por: Ghirardi, v, et al.
Publicado: (2023)

Stat1 confers sensitivity to radiation in cervical cancer cells by controlling Parp1 levels: a new perspective for Parp1 inhibition
por: Raspaglio, Giuseppina, et al.
Publicado: (2021)

What’s beyond BRCA Mutational Status in High Grade Serous Ovarian Cancer? The Impact of Hormone Receptor Expression in a Large BRCA-Profiled Ovarian Cancer Patient Series: A Retrospective Cohort Study
por: Perrone, Emanuele, et al.
Publicado: (2022)

Dual inhibition of CDK12 and CDK13 uncovers actionable vulnerabilities in patient-derived ovarian cancer organoids
por: Cesari, Eleonora, et al.
Publicado: (2023)

Cytoreductive Surgery Plus Platinum-Based Hyperthermic Intraperitoneal Chemotherapy in Epithelial Ovarian Cancer: A Promising Integrated Approach to Improve Locoregional Control
por: Petrillo, Marco, et al.
Publicado: (2016)

Expression of the Glioma-Associated Oncogene Homolog 1 (Gli1) in Advanced Serous Ovarian Cancer Is Associated with Unfavorable Overall Survival
por: Ciucci, Alessandra, et al.
Publicado: (2013)

A combined ANXA2-NDRG1-STAT1 gene signature predicts response to chemoradiotherapy in cervical cancer
por: Buttarelli, Marianna, et al.
Publicado: (2019)

Trametinib response in heavily pretreated high-grade ovarian cancer: One step towards precision medicine
por: Cappuccio, Serena, et al.
Publicado: (2020)

The relevance of prelamin A and RAD51 as molecular biomarkers in cervical cancer
por: Leonardi, Simona, et al.
Publicado: (2017)

Estrogens Counteract Platinum-Chemosensitivity by Modifying the Subcellular Localization of MDM4
por: Lucà, Rossella, et al.
Publicado: (2019)

Determining clinically meaningful decline in preclinical Alzheimer disease
por: Insel, Philip S., et al.
Publicado: (2019)

Deep-Learning to Predict BRCA Mutation and Survival from Digital H&E Slides of Epithelial Ovarian Cancer
por: Nero, Camilla, et al.
Publicado: (2022)

Hyperthermic Intraperitoneal Chemotherapy (HIPEC): New Approaches and Controversies on the Treatment of Advanced Epithelial Ovarian Cancer—Systematic Review and Meta-Analysis
por: Della Corte, Luigi, et al.
Publicado: (2023)

RE: Pattern of and reason for postoperative residual disease in patients with advanced ovarian cancer following upfront radical debulking surgery
por: Fagotti, A, et al.
Publicado: (2016)

The prognostic role of systemic inflammatory markers in apparent early-stage ovarian cancer
por: Bizzarri, Nicolò, et al.
Publicado: (2022)

Gender Effect in Experimental Models of Human Medulloblastoma: Does the Estrogen Receptor β Signaling Play a Role?
por: Ciucci, Alessandra, et al.
Publicado: (2014)

The interaction of β-arrestin1 with talin1 driven by endothelin A receptor as a feature of α5β1 integrin activation in high-grade serous ovarian cancer
por: Masi, Ilenia, et al.
Publicado: (2023)

Global Considerations in Hierarchical Clustering Reveal Meaningful Patterns in Data
por: Varshavsky, Roy, et al.
Publicado: (2008)

Preclinical and Clinical Immunotherapeutic Strategies in Epithelial Ovarian Cancer
por: Martinez, Alejandra, et al.
Publicado: (2020)

Mouse models of epithelial ovarian cancer for preclinical studies
por: Karakashev, Sergey, et al.
Publicado: (2021)

Minimally-Invasive Secondary Cytoreduction in Recurrent Ovarian Cancer
por: Certelli, Camilla, et al.
Publicado: (2023)

Evolution of Clinical Trials in Ovarian Cancer Management over the Past 20 Years: Never Settle Down, Always Go Beyond
por: De Felice, Francesca, et al.
Publicado: (2021)

Utility of the Dependence Scale in dementia: validity, meaningfulness, and health economic considerations
por: Zhu, Carolyn W., et al.
Publicado: (2018)

Considerations for supporting meaningful stakeholder engagement in global mental health research
por: Murphy, Jill K.
Publicado: (2022)

Preoperative Anti-Class III β-Tubulin Antibodies As Relevant Clinical Biomarkers in Ovarian Cancer
por: Martinelli, Enrica, et al.
Publicado: (2018)

Extreme complications related to bevacizumab use in the treatment of ovarian cancer: a case series from a III level referral centre and review of the literature
por: Turco, Luigi Carlo, et al.
Publicado: (2020)

Tumor BRCA testing in ovarian cancer and EQA scheme: our experience of a critical evaluation
por: De Paolis, Elisa, et al.
Publicado: (2021)

Immunoradiometric and immunohistochemical analysis of Cathepsin D in ovarian cancer: lack of association with clinical outcome.
por: Ferrandina, G., et al.
Publicado: (1998)

Preclinical and Clinical Evidence of Lurbinectedin in Ovarian Cancer: Current Status and Future Perspectives
por: Musacchio, Lucia, et al.
Publicado: (2022)

Immunotherapy in cervical cancer: the advent of precision medicine
por: De Felice, Francesca, et al.
Publicado: (2020)

Pathological Chemotherapy Response Score in Patients Affected by High Grade Serous Ovarian Carcinoma: The Prognostic Role of Omental and Ovarian Residual Disease
por: Santoro, Angela, et al.
Publicado: (2019)

Patient-Derived Xenograft Models of Epithelial Ovarian Cancer for Preclinical Studies
por: Heo, Eun Jin, et al.
Publicado: (2017)

NLR and BRCA mutational status in patients with high grade serous advanced ovarian cancer
por: Marchetti, Claudia, et al.
Publicado: (2021)

Epithelial ovarian cancer relapsing as isolated lymph node disease: natural history and clinical outcome
por: Legge, Francesco, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_0f632vj5ofrcplb2gjm9uka1b3